Quick Takeaways
- VMD Sciences has expanded its support efforts for large animal veterinarians facing therapeutic limitations caused by the ongoing US shortage of Buscopan (N-butylscopolammonium bromide). The company is helping practitioners access EU-approved Buscopan Compositum Solution for Injection through compliant importation pathways to maintain continuity of care for equine colic and related conditions
- Alongside addressing supply shortages, VMDS is also increasing its focus on emerging infectious disease threats linked to the spread of the Asian longhorned tick across the US. The company is supporting access to internationally licensed antiparasitic therapies and associated treatments to help veterinarians manage diseases such as Theileriosis, where domestic therapeutic options remain limited
- VMDS works with veterinarians to navigate international sourcing, regulatory requirements, and importation logistics for essential veterinary medicines, aiming to strengthen treatment continuity amid supply chain disruptions and evolving herd health risks. The company noted that all sourcing and distribution activities are conducted in compliance with applicable importation, safety, and traceability regulations
Why It Matters?
VMD Sciences is positioning itself as a supply-chain backup for large-animal practice, which matters because drug shortages can quickly disrupt equine colic care and other urgent treatments. The market implication is that it can win relevance by helping vets source approved alternatives when domestic products run short, rather than competing only on branded therapeutics.
Its growing focus on tick-borne and emerging infectious disease support also points to a broader niche: being the go-to partner for hard-to-access veterinary medicines where local options are limited. That could make VMDS more valuable to practices dealing with shortage risk, biosecurity concerns, and cross-border import complexity.
Source: Businesswire
